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rafts, where it comes into proximity with Rho. While theMuscle or Fat? Rho Bridges the GAP
authors speculate that RhoGAP is a direct substrate of
the receptor, it also remains possible that this phosphor-
ylation is catalyzed by Src, which is activated by IGF1
(Peterson et al., 1996), and has been shown to readilyMesenchymal stem cells can differentiate into muscle
phosphorylate the GAP (Brouns et al., 2001). Thus, IGF1or fat cells, depending on the exposure to growth fac-
effectively acts as a negative regulator of Rho, stimulat-tors. The Rho GTPase appears to play a crucial role
ing GTP hydrolysis and inactivation of the protein.in this decision of cellular fate, promoting myogenesis
The downstream actions of Rho to control cellularand inhibiting adipogenesis.
fate are even more interesting. Dominant-negative forms
of Rho or overexpression of the inhibitory RhoGDI blockThe extent to which we form fat and muscle cells during
myogenesis, and overexpression of constitutively activeand after embryonic development determines how we
Rho blocks adipogenesis. Sordella et al. (2003) proposehandle energy, respond to hormonal and nutritional sta-
that the well-established role of Rho to regulate the actintus, and deal with stress, not to mention influencing our
cytoskeleton is not involved in this process, but thatappearance. Recent studies have suggested that fat
ROK acts as the major effector in cell fate determination.and muscle cells work together; fat cells control the ebb
An inhibitor of this kinase blocks myogenesis, and re-and flow of lipid metabolism, generating not only fatty
stores adipogenesis inhibited by disruption of the Rho-acids in response to hormones and nutrients, but also
GAP gene. Two pathways are proposed to mediate thisproducing hormones that directly and indirectly regulate
process. ROK can catalyze the serine phosphorylationthe ability of muscle cells to use or store energy. (Kahn
of IRS, reducing its tyrosine phosphorylation by the IGF1and Flier, 2000) Thus, the coordinated differentiation of
receptor, as has been shown for various MAP kinasethese cells has been among the most intensely studied
pathways (Hirosumi et al., 2002). This serine phosphory-problems in development.
lation could conceivably block the activation of PIMesenchymal stem cells are capable of differentiating
3-kinase by IGF1, without impacting stimulation of theinto a number of different cell types, including osteo-
MAP kinase pathway. The significance of this interestingblasts, chondrocytes, adipocytes or myocytes, and the
observation will require a careful analysis of the rolesame population of marrow-derived stromal cells can
of the putative ROK phosphorylation site on the IRSgive rise to fat or bone cells or in some cases muscle
proteins, to evaluate the degree to which preventingcells. While the transcriptional programs that accom-
phosphorylation might influence IGF1 action in this cel-pany the late stages of adipocyte or myocyte differentia-
lular context. It is also proposed that the tyrosine phos-tion are well studied (Rosen and Spiegelman, 2000), the
phatase SHP2 might play an important role, since itmolecular events that determine the ultimate fate of early
associates with the RhoGAP upon tyrosine phosphory-precursor cells are poorly understood. Studies on pre-
lation of the latter protein, and might catalyze the de-determined clonal lines have revealed insulin like growth
phosphorylation of the GAP, reducing its activity orfactor 1 (IGF1) as a crucial player in both adipocyte
changing its localization and indirectly increasing Rho
(Rosen and Spiegelman, 2000) and myocyte (Coolican et
activity. This is an interesting idea, but is confounded
al., 1997) differentiation. However, the story is complex,
by the well-established role of SHP2 as a positive ef-
since in both cases IGF1 paradoxically stimulates both
fector of the MAP kinase pathway (Milarski and Saltiel,
proliferation and differentiation, while growth arrest and 1994), which is reduced during myocyte differentiation.
withdrawal from the cell cycle seem to be necessary. Not (Coolican et al., 1997).
surprisingly, the signaling pathways that govern these As is the case with most new insights, more questions
complex events have remained confusing, and as is the arise than are answered. One wonders whether a critical
case for metabolic regulation by its cousin insulin (Saltiel role for changes in the actin cytoskeleton can be com-
and Kahn, 2001), it has been difficult to explain how pletely ruled out as a mechanism, since actin structure in
divergent signals emanating from the IGF1 receptor co- fibroblasts, adipocytes, and myocytes are very different,
ordinate adipogenic and myogenic gene expression. and these changes occur early in the differentiation pro-
Sordella et al. (2003 [this issue of Cell]) have shed new cesses. Do the dramatic effects of RhoGAP knockout
light on this confusion by identifying a role for p190 reflect the impact of Rho itself, or are there other targets
RhoGAP, a regulator of RhoA and perhaps other Rho of the GAP? Numerous other Rho family members are
family proteins, in modulating the choice between adi- expressed in these mesenchymal cells, and undergo
pogenesis and myogenesis. Targeted disruption of the similar changes in activation state during differentiation
RhoGAP gene resulted in increased activity of Rho, and (Hall, 1998). Likewise, it remains possible that RhoGAP
the subsequent activation of downstream Rho targets, acts as an effector molecule, rather than just a signal
including the Rho kinase ROK. While deletion of the terminator, influencing cell fate determination in a cell
gene was lethal, there was a reduction in adipocyte type-specific context. The precise role of ROK in the
formation from embryos derived from knockout mice, differentiating process is also intriguing, although care
suggesting that Rho activation might favor myogenesis must be taken when relying on a single pharmacological
over adipogenesis. inhibitor. Although ROK has been implicated in numer-
Because Rho is not a well-known target of IGF1 action, ous processes (Uehata et al., 1997), its potential targets
the authors looked both up and downstream of RhoGAP in the regulation of myogenesis/adipogenesis are many.
to explore mechanisms involved in this interesting phe- While a good case is made for feedback inhibition of
nomenon. RhoGAP undergoes tyrosine phosphorylation IGF signaling, ROK might also phosphorylate proteins
that directly influence transcription, including transcrip-in response to IGF1, stimulating its translocation to lipid
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tion factors. Finally, the role of lipid rafts in localizing
Rho and RhoGAP provides another potential layer of
regulation, since there are numerous other signaling
molecules that reside in these plasma membrane sub-
domains. Whether or not Rho itself is highly enriched in
rafts is uncertain, and how phosphorylation of RhoGAP
might direct the protein here is of interest; probably
resulting from another interaction with a raft-associated
protein. Together these questions provide fertile ground
for a new direction to study the decisions made by these
early stem cells to become fat laden or muscular.
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